Dexmedetomidine hydrochloride plus sufentanil citrate inhibits glucose metabolism and epithelial‑mesenchymal transition in human esophageal squamous carcinoma KYSE30 cells by modulating the JAK/STAT3/HIF‑1&alpha; axis

Li,Weijing; Wang,Yong; Li,Xiaolin; Wu,Han; Jia,Li

doi:10.3892/ol.2024.14406

Dexmedetomidine hydrochloride plus sufentanil citrate inhibits glucose metabolism and epithelial‑mesenchymal transition in human esophageal squamous carcinoma KYSE30 cells by modulating the JAK/STAT3/HIF‑1α axis

Authors:
- Weijing Li
- Yong Wang
- Xiaolin Li
- Han Wu
- Li Jia
View Affiliations

Affiliations: Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: April 18, 2024 https://doi.org/10.3892/ol.2024.14406
Article Number: 273
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dexmedetomidine hydrochloride (DEX‑HCl) and sufentanil citrate (SFC) are commonly used anesthetic drugs for esophageal cancer (EC) surgery. The present study was performed to investigate the effect of DEX‑HCl and SFC treatment on glucose metabolism and epithelial‑mesenchymal transition in EC. Cell counting kit‑8 (CCK8), clonogenic, wound healing and Transwell migration assays were performed to assess the effects of the DEX‑HCl and SFC on KYSE30 cell proliferation, invasion and migration. Changes in lactate and glucose levels in KYSE30 cells were also detected. Western blot analysis was used to determine the protein expression levels of the JAK/STAT signaling pathway and glucose metabolism‑related proteins. The results of CCK8, clonogenic and wound healing assays demonstrated that DEX‑HCl and SFC inhibited KYSE30 cell proliferation, invasion and migration. Similarly, the combined DEX‑HCl and SFC treatment significantly reduced lactate production, ATP production and glucose levels in KYSE30 cells. Western blotting indicated that DEX‑HCl and SFC could reduce JAK/STAT and metastasis‑related protein expression. Demonstrating a reduction in Hexokinase 2, matrix metallopeptidase 2 and 9, N‑cadherin and lactate dehydrogenase A protein expression levels. The effects of DEX‑HCl and SFC combined treatment were counteracted by the addition of JAK/STAT pathway activator RO8191, which suggested that DEX‑HCl and SFC could serve a role in mediating the JAK/STAT signaling pathway in KYSE30 cells.

View Figures

View References

1	Liu CQ, Ma YL, Qin Q, Wang PH, Luo Y, Xu PF and Cui Y: Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 14:3–11. 2023. View Article : Google Scholar : PubMed/NCBI
2	Liu Z, Zhao Y, Kong P, Liu Y, Huang J, Xu E, Wei W, Li G, Cheng X, Xue L, et al: Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell. 41:181–195. 2023. View Article : Google Scholar
3	Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J and Arnold M: The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020. Gastroenterology. 163:649–658. 2022. View Article : Google Scholar : PubMed/NCBI
4	Li P, Jing J, Liu W, Wang J, Qi X and Zhang G: Spatiotemporal patterns of esophageal cancer burden attributable to behavioral, metabolic, and dietary risk factors from 1990 to 2019: Longitudinal observational study. JMIR Public Health Surveill. 9:e460512023. View Article : Google Scholar
5	Codipilly DC and Wang KK: Squamous cell carcinoma of the esophagus. Gastroenterol Clin North Am. 51:457–484. 2022. View Article : Google Scholar : PubMed/NCBI
6	Lu D, Wu X, Wu W, Wu S, Li H, Zhang Y, Yan X, Zhai J, Dong X, Feng S, et al: Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer. Cell Death Dis. 14:8432023. View Article : Google Scholar : PubMed/NCBI
7	Wang S, Zheng R, Arnold M, Abnet C, Zeng H, Zhang S, Chen R, Sun K, Li L, An L, et al: Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype. Int J Cancer. 151:1447–1461. 2022. View Article : Google Scholar : PubMed/NCBI
8	Manfioletti G and Fedele M: Epithelial-mesenchymal transition (EMT). Int J Mol Sci. 24:113862023. View Article : Google Scholar
9	Lu W and Kang Y: Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 49:361–374. 2019. View Article : Google Scholar
10	Counihan JL, Grossman EA and Nomura DK: Cancer metabolism: Current understanding and therapies. Chem Rev. 118:6893–6923. 2018. View Article : Google Scholar : PubMed/NCBI
11	Zhang M, Wei T, Zhang X and Guo D: Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy. Front Immunol. 13:9374062022. View Article : Google Scholar
12	Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D and Sun S: The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 80:1062102020. View Article : Google Scholar
13	Zhang P, Li Z and Yang G: Silencing of ISLR inhibits tumour progression and glycolysis by inactivating the IL-6/JAK/STAT3 pathway in non-small cell lung cancer. Int J Mol Med. 48:2222021. View Article : Google Scholar : PubMed/NCBI
14	Xiao C, Zhang W, Hua M, Chen H, Yang B, Wang Y and Yang Q: RNF7 inhibits apoptosis and sunitinib sensitivity and promotes glycolysis in renal cell carcinoma via the SOCS1/JAK/STAT3 feedback loop. Cell Mol Biol Lett. 27:362022. View Article : Google Scholar
15	Lei K, Du W, Lin S, Yang L, Xu Y, Gao Y, Xu B, Tan S, Xu Y, Qian X, et al: 3B, a novel photosensitizer, inhibits glycolysis and inflammation via miR-155-5p and breaks the JAK/STAT3/SOCS1 feedback loop in human breast cancer cells. Biomed Pharmacother. 82:141–150. 2016. View Article : Google Scholar : PubMed/NCBI
16	You Z, Xu D, Ji J, Guo W, Zhu W and He J: JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma. Clin Transl Oncol. 14:143–149. 2012. View Article : Google Scholar
17	Zhao X, Tang YP, Wang CY, Wu JX and Ye F: Prognostic values of STAT3 and HIF-1lα in esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 23:3351–3357. 2019.
18	Fang J, Chu L, Li C, Chen Y, Hu F, Zhang X, Zhao H, Liu Z and Xu Q: JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway. Oncol Rep. 33:494–502. 2015. View Article : Google Scholar : PubMed/NCBI
19	Yang Y, Jin G, Liu H, Liu K, Zhao J, Chen X, Wang D, Bai R, Li X, Jang Y, et al: Metformin inhibits esophageal squamous cell carcinoma-induced angiogenesis by suppressing JAK/STAT3 signaling pathway. Oncotarget. 8:74673–74687. 2017. View Article : Google Scholar
20	Garcia SN, Guedes RC and Marques MM: Unlocking the potential of HK2 in cancer metabolism and therapeutics. Curr Med Chem. 26:7285–7322. 2019. View Article : Google Scholar : PubMed/NCBI
21	Zhang L, Jiang C, Zhong Y, Sun K, Jing H, Song J, Xie J, Zhou Y, Tian M, Zhang C, et al: STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2. Nat Cell Biol. 25:1208–1222. 2023. View Article : Google Scholar
22	Xun S and Zheng R: Dexmedetomidine alleviates neuropathic pain by regulating JAK/STAT pathway in rats. J Cell Biochem. 121:2277–2283. 2020. View Article : Google Scholar : PubMed/NCBI
23	Si Y, Bao H, Han L, Shi H, Zhang Y, Xu L, Liu C, Wang J, Yang X, Vohra A and Ma D: Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation. J Transl Med. 11:1412013. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Jiang W and Luo X: Remifentanil combined with dexmedetomidine on the analgesic effect of breast cancer patients undergoing modified radical mastectomy and the influence of perioperative T lymphocyte subsets. Front Surg. 9:10166902022. View Article : Google Scholar : PubMed/NCBI
25	Cai Q, Liu G, Huang L, Guan Y, Wei H, Dou Z, Liu D, Hu Y and Gao M: The role of dexmedetomidine in tumor-progressive factors in the perioperative period and cancer recurrence: A narrative review. Drug Des Devel Ther. 16:2161–2175. 2022. View Article : Google Scholar : PubMed/NCBI
26	Zhang H, Qu M, Guo K, Wang Y, Gu J, Wu H, Zhu X, Sun Z, Cata JP, Chen W and Miao C: Intraoperative lidocaine infusion in patients undergoing pancreatectomy for pancreatic cancer: A mechanistic, multicentre randomised clinical trial. Br J Anaesth. 129:244–253. 2022. View Article : Google Scholar : PubMed/NCBI
27	Ruijter JM, Barnewall RJ, Marsh IB, Szentirmay AN, Quinn JC, van Houdt R, Gunst QD and van den Hoff MJB: Efficiency correction is required for accurate quantitative PCR analysis and reporting. Clin Chem. 67:829–842. 2021. View Article : Google Scholar : PubMed/NCBI
28	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
29	Meng J, Zhang C, Zhu N, Zhang C, Liu M, Han Z and Li Y: EPN3 plays oncogenic role in non-small cell lung cancer by activating the JAK1/2-STAT3 pathway. Environ Toxicol. 38:1968–1979. 2023. View Article : Google Scholar
30	Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, Chattopadhyay I, Rao PV and Ghavami S: Autophagy and EMT in cancer and metastasis: Who controls whom? Biochim Biophys Acta Mol Basis Dis. 1868:1664312022. View Article : Google Scholar : PubMed/NCBI
31	Zhang X, Shi G, Gao F, Liu P, Wang H and Tan X: TSPAN1 upregulates MMP2 to promote pancreatic cancer cell migration and invasion via PLCγ. Oncol Rep. 41:2117–2125. 2019.PubMed/NCBI
32	Zhang L, Xi RX and Zhang XZ: Matrix metalloproteinase variants associated with risk and clinical outcome of esophageal cancer. Genet Mol Res. 14:4616–4624. 2015. View Article : Google Scholar : PubMed/NCBI
33	Xu XL, Ling ZQ, Chen SZ, Li B, Ji WH and Mao WM: The impact of E-cadherin expression on the prognosis of esophageal cancer: A meta-analysis. Dis Esophagus. 27:79–86. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zhu S, Liu J, Min L, Sun X, Guo Q, Li H, Zhang Z, Zhao Y, Gu J and Zhang S: Cadherin expression shift could well distinguish esophageal squamous cell carcinoma from non- cancerous esophageal tissues. Oncol Res Treat. 41:380–385. 2018. View Article : Google Scholar
35	Mendonsa AM, Na TY and Gumbiner BM: E-cadherin in contact inhibition and cancer. Oncogene. 37:4769–4780. 2018. View Article : Google Scholar : PubMed/NCBI
36	Parker J, Hockney S, Blaschuk OW and Pal D: Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia. Expert Rev Mol Med. 25:e162023. View Article : Google Scholar : PubMed/NCBI
37	Lou C, Wu K, Shi J, Dai Z and Xu Q: N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor. J Immunother Cancer. 10:e0050612022. View Article : Google Scholar : PubMed/NCBI
38	Mariotti A, Perotti A, Sessa C and Rüegg C: N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs. 16:451–465. 2007. View Article : Google Scholar : PubMed/NCBI
39	Yoshio T, Ishiyama A, Tsuchida T, Yoshimizu S, Horiuchi Y, Omae M, Hirasawa T, Yamamoto Y, Sano H, Yokota M and Fujisaki J: Efficacy of novel sedation using the combination of dexmedetomidine and midazolam during endoscopic submucosal dissection for esophageal squamous cell carcinoma. Esophagus. 16:285–291. 2019. View Article : Google Scholar : PubMed/NCBI
40	Che J, Liu M and Lv H: Dexmedetomidine disrupts esophagus cancer tumorigenesis by modulating circ_0003340/miR-198/HMGA2 axis. Anticancer Drugs. 33:448–458. 2022. View Article : Google Scholar : PubMed/NCBI
41	Tang H, Li C, Wang Y and Deng L: Sufentanil inhibits the proliferation and metastasis of esophageal cancer by inhibiting the NF-κB and snail signaling pathways. J Oncol. 2021:75861002021. View Article : Google Scholar
42	Kocianova E, Piatrikova V and Golias T: Revisiting the warburg effect with focus on lactate. Cancers (Basel). 14:60282022. View Article : Google Scholar : PubMed/NCBI
43	Zhong X, He X, Wang Y, Hu Z, Huang H, Zhao S, Wei P and Li D: Warburg effect in colorectal cancer: The emerging roles in tumor microenvironment and therapeutic implications. J Hematol Oncol. 15:1602022. View Article : Google Scholar
44	Chelakkot C, Chelakkot VS, Shin Y and Song K: Modulating glycolysis to improve cancer therapy. Int J Mol Sci. 24:26062023. View Article : Google Scholar
45	Zhang K, Zhang T, Yang Y, Tu W, Huang H, Wang Y, Chen Y, Pan K and Chen Z: N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming. Theranostics. 12:4802–4817. 2022. View Article : Google Scholar : PubMed/NCBI
46	Jacquet P and Stephanou A: Searching for the metabolic signature of cancer: A review from warburg's time to now. Biomolecules. 12:14122022. View Article : Google Scholar : PubMed/NCBI
47	Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et al: LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24:657–671. 2016. View Article : Google Scholar : PubMed/NCBI
48	Dinakar YH, Kumar H, Mudavath SL, Jain R, Ajmeer R and Jain V: Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors. Life Sci. 309:1209962022. View Article : Google Scholar
49	Malekan M, Ebrahimzadeh MA and Sheida F: The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma. Biomed Pharmacother. 141:1118732021. View Article : Google Scholar : PubMed/NCBI
50	Hu L, Liu R and Zhang L: Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors. Int Immunopharmacol. 111:1090952022. View Article : Google Scholar
51	Hu X, Yuan L and Ma T: Mechanisms of JAK-STAT signaling pathway mediated by CXCL8 gene silencing on epithelial-mesenchymal transition of human cutaneous melanoma cells. Oncol Lett. 20:1973–1981. 2020. View Article : Google Scholar
52	Li J, Shen J, Wang Z, Xu H, Wang Q, Chai S, Fu P, Huang T, Anas O, Zhao H, et al: ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1alpha signaling axis. Sci Rep. 9:139042019. View Article : Google Scholar : PubMed/NCBI